Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.

Details

Request a copyRequest a copy
Serval ID
serval:BIB_9C2FB806ED0B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Efficacy and Safety of Dolutegravir Plus Emtricitabine vs Combined Antiretroviral Therapy for the Maintenance of HIV Suppression: Results Through Week 144 of the SIMPL'HIV Trial.
Journal
Open forum infectious diseases
Author(s)
Marinosci A., Sculier D., Wandeler G., Yerly S., Stoeckle M., Bernasconi E., Braun D.L., Vernazza P., Cavassini M., Decosterd L., Günthard H.F., Schmid P., Limacher A., Branca M., Calmy A.
Working group(s)
Swiss HIV Cohort Study, Swiss, H. I. V. Cohort Study
Contributor(s)
Sudan R., Barbieux C., Da Silva T., Bernasconi-Meyer B., Metzner K.J.
ISSN
2328-8957 (Print)
ISSN-L
2328-8957
Publication state
Published
Issued date
11/2024
Peer-reviewed
Oui
Editor
Sudan R Barbieux C. Da Silva T. Bernasconi-Meyer B. Metzner K. J.
Volume
11
Number
11
Pages
ofae618
Language
english
Notes
Publication types: Clinical Trial ; Journal Article
Publication Status: epublish
Abstract
The SIMPL'HIV study investigated whether switching to dolutegravir (DTG) + emtricitabine (FTC) was noninferior to continuing combined antiretroviral therapy for maintaining HIV-1 suppression at 144 weeks. The study demonstrated that viral suppression, CD4 gains, adverse events, quality of life, and patient satisfaction were comparable between groups, confirming DTG + FTC's safety and efficacy for long-term management of HIV-1 infection.
Keywords
HIV-1 dual therapy, dolutegravir + emtricitabine, maintenance treatment, patient satisfaction, quality of life
OAI-PMH
oai:serval.unil.ch:BIB_9C2FB806ED0B
DOI
10.1093/ofid/ofae618
Pubmed
39507885
Open Access
Yes
Create date
11/11/2024 15:47
Last modification date
12/11/2024 7:05
Usage data